Skip to main content
SpringerLink
Log in

Second- or third-line lorlatinib appears cost effective for ALK-positive NSCLC in Sweden

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was affiliated with, and funded by Pfizer.

Reference

  • Nilsson FOL, et al. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden. . PharmacoEconomics : 3 Jun 2021. Available from: URL: http://doi.org/10.1007/s40273-021-01015-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Second- or third-line lorlatinib appears cost effective for ALK-positive NSCLC in Sweden. PharmacoEcon Outcomes News 881, 27 (2021). https://doi.org/10.1007/s40274-021-7823-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7823-8

Search

Navigation